Orion Pharma Limited IPO

Orion Pharmaceutical Limited Primary Initial public offering (IPO) has approved share market control agency said. Securities and Exchange Commission on Tuesday approved the regular meetings of this.

Orion Pharma Ltd. IPO Draw Result

Orion Pharma Limited
 (As per abridged version of Prospectus) 
Nature of Business
The Company owns and operates a modern
pharmaceuticals factory  and produces and sells
pharmaceuticals drugs and medicine.
Major Product
Enliven (Imatinib Mesylate) capsule, Betacal (Atenolol
plus amlodipine) tab, Vert ex injection (Ceftriaxone
sodium), Clognil plus (Clopi dogrel+ Aspirin) tab, Pep
(Zinc sulphate) Tab/Syrup, Deslor (Desloratadine)
Tab/Syp, Axet (Cefurox ime) Tab/inj, Pedicef
(Cefpodoxime) susp, Azalid (Azithromycin) Tab/Sus,
Truso (Cefixime) Cap/sus.
Subscription Open   January 06, 2013
Subscription Close   January 10, 2013
Subscription period
for NRB
January 06, 2013 to  January 19, 2013
Authorized Capital  Tk. 5,000,000,000 
Pre- IPO paid-up
Capital
Tk. 1,550,000,000 
IPO size in shares
40,000,000
IPO size in Tk. at
face value
Tk. 400,000,000 
IPO size in Tk. at
offer price
Tk. 2,400,000,000 (including premium of Tk.
2,000,000,000).
Post IPO Paid-up
Capital
Tk. 1,950,000,000 
Face Value  per
share
Tk. 10.00 
Offer Price per
share     
Tk. 60.00 (including a premium of Tk. 50.00 per share).
Market Lot (Shares)  100
Use of IPO Proceeds
For construction of expansion project of Orion Pharma
Limited at Valuka, Mymensingh in terms of the
expansion of the existing product line along with the
addition of new product lines.
NAV per share          
Tk. 76.87 (considering revaluation reserve) as on
December 31, 2011.  
Tk. 61.43 (without revaluation reserve) as on December
31, 2011.
EPS  Tk. 5.57 for the year ended December 31, 2011.
Issue Manager            ICB Capital Management Limited

Auditors  S. F. Ahmed & Co.

Website  www.orion-group.net

Orion Pharmaceutical Limited for four million shares from 240 million taka will leave the market. Premium 60 taka per share 50 per issue received the approval. ICB Capital Management Limited, as manager of the Establishment issue.